Related Experiment Video

Updated: Sep 3, 2025

Application of Electrophysiology Measurement to Study the Activity of Electro-Neutral Transporters
11:51

Application of Electrophysiology Measurement to Study the Activity of Electro-Neutral Transporters

Published on: February 3, 2018

7.0K

Na+/H+ Exchanger 1, a Potential Therapeutic Drug Target for Cardiac Hypertrophy and Heart Failure

Huiting Xia1, Aqeela Zahra1, Meng Jia2,3,4

  • 1School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan 430070, China.

Pharmaceuticals (Basel, Switzerland)
|July 27, 2022
PubMed

Insights

The Na+/H+ exchanger 1 (NHE1) plays a role in cardiac hypertrophy and heart failure. This review explores how NHE1 contributes to these conditions and potential therapeutic mechanisms.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Cardiac hypertrophy, an enlarged heart mass, can progress to heart failure.
  • Myocardial infarction and subsequent ischemia-reperfusion injury contribute to heart failure incidence.
  • Na+/H+ exchangers (NHEs) are critical membrane transporters, with NHE1 being widely expressed, particularly in the heart.

Purpose of the Study:

  • To elucidate the role of NHE1 in cardiac hypertrophy and heart failure.
  • To investigate the molecular mechanisms underlying NHE1's involvement in these cardiac conditions.

Main Methods:

  • This review synthesizes findings from preclinical research on NHE1.
  • Analysis of the molecular pathways involving NHE1 in cardiac pathophysiology.

Main Results:

  • NHE1 activity increases during myocardial ischemia-reperfusion, leading to Na+ influx.
  • This Na+ overload results in intracellular Ca2+ accumulation and myocardial injury.
  • Preclinical studies indicate NHE1's involvement in cardiac hypertrophy and heart failure progression.

Conclusions:

  • NHE1 is implicated in the development of cardiac hypertrophy and heart failure.
  • Understanding NHE1's mechanisms may reveal therapeutic targets for heart disease.

Keywords:
Na+/H+ exchanger 1cardiac hypertrophyheart failureischemia-reperfusion injury

More Related Videos

Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane07:38

Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane

Published on: March 30, 2015

9.3K
Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes12:49

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Published on: September 24, 2013

24.6K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
497
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
704
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
472
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31